18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries

      research-article
      1 , , 1 , 2 , 2 , 3 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 10 , 11 , 1 , 12 , 12 , 13 , 13 , 14 , 15 , 14 , 16 , 17 , 18 , 17 , 18 , 19 , 19 , 20 , 20 , 1 , 1 , 1
      Influenza and Other Respiratory Viruses
      John Wiley and Sons Inc.
      epidemiology, respiratory syncytial virus, seasonality, surveillance

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Respiratory syncytial virus (RSV) infections are one of the leading causes of lower respiratory tract infections and have a major burden on society. For prevention and control to be deployed effectively, an improved understanding of the seasonality of RSV is necessary.

          Objectives

          The main objective of this study was to contribute to a better understanding of RSV seasonality by examining the GERi multi‐country surveillance dataset.

          Methods

          RSV seasons were included in the analysis if they contained ≥100 cases. Seasonality was determined using the “average annual percentage” method. Analyses were performed at a subnational level for the United States and Brazil.

          Results

          We included 601 425 RSV cases from 12 countries. Most temperate countries experienced RSV epidemics in the winter, with a median duration of 10–21 weeks. Not all epidemics fit this pattern in a consistent manner, with some occurring later or in an irregular manner. More variation in timing was observed in (sub)tropical countries, and we found substantial differences in seasonality at a subnational level. No association was found between the timing of the epidemic and the dominant RSV subtype.

          Conclusions

          Our findings suggest that geographical location or climatic characteristics cannot be used as a definitive predictor for the timing of RSV epidemics and highlight the need for (sub)national data collection and analysis.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017

          Summary Background Global development goals increasingly rely on country-specific estimates for benchmarking a nation's progress. To meet this need, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 estimated global, regional, national, and, for selected locations, subnational cause-specific mortality beginning in the year 1980. Here we report an update to that study, making use of newly available data and improved methods. GBD 2017 provides a comprehensive assessment of cause-specific mortality for 282 causes in 195 countries and territories from 1980 to 2017. Methods The causes of death database is composed of vital registration (VR), verbal autopsy (VA), registry, survey, police, and surveillance data. GBD 2017 added ten VA studies, 127 country-years of VR data, 502 cancer-registry country-years, and an additional surveillance country-year. Expansions of the GBD cause of death hierarchy resulted in 18 additional causes estimated for GBD 2017. Newly available data led to subnational estimates for five additional countries—Ethiopia, Iran, New Zealand, Norway, and Russia. Deaths assigned International Classification of Diseases (ICD) codes for non-specific, implausible, or intermediate causes of death were reassigned to underlying causes by redistribution algorithms that were incorporated into uncertainty estimation. We used statistical modelling tools developed for GBD, including the Cause of Death Ensemble model (CODEm), to generate cause fractions and cause-specific death rates for each location, year, age, and sex. Instead of using UN estimates as in previous versions, GBD 2017 independently estimated population size and fertility rate for all locations. Years of life lost (YLLs) were then calculated as the sum of each death multiplied by the standard life expectancy at each age. All rates reported here are age-standardised. Findings At the broadest grouping of causes of death (Level 1), non-communicable diseases (NCDs) comprised the greatest fraction of deaths, contributing to 73·4% (95% uncertainty interval [UI] 72·5–74·1) of total deaths in 2017, while communicable, maternal, neonatal, and nutritional (CMNN) causes accounted for 18·6% (17·9–19·6), and injuries 8·0% (7·7–8·2). Total numbers of deaths from NCD causes increased from 2007 to 2017 by 22·7% (21·5–23·9), representing an additional 7·61 million (7·20–8·01) deaths estimated in 2017 versus 2007. The death rate from NCDs decreased globally by 7·9% (7·0–8·8). The number of deaths for CMNN causes decreased by 22·2% (20·0–24·0) and the death rate by 31·8% (30·1–33·3). Total deaths from injuries increased by 2·3% (0·5–4·0) between 2007 and 2017, and the death rate from injuries decreased by 13·7% (12·2–15·1) to 57·9 deaths (55·9–59·2) per 100 000 in 2017. Deaths from substance use disorders also increased, rising from 284 000 deaths (268 000–289 000) globally in 2007 to 352 000 (334 000–363 000) in 2017. Between 2007 and 2017, total deaths from conflict and terrorism increased by 118·0% (88·8–148·6). A greater reduction in total deaths and death rates was observed for some CMNN causes among children younger than 5 years than for older adults, such as a 36·4% (32·2–40·6) reduction in deaths from lower respiratory infections for children younger than 5 years compared with a 33·6% (31·2–36·1) increase in adults older than 70 years. Globally, the number of deaths was greater for men than for women at most ages in 2017, except at ages older than 85 years. Trends in global YLLs reflect an epidemiological transition, with decreases in total YLLs from enteric infections, respiratory infections and tuberculosis, and maternal and neonatal disorders between 1990 and 2017; these were generally greater in magnitude at the lowest levels of the Socio-demographic Index (SDI). At the same time, there were large increases in YLLs from neoplasms and cardiovascular diseases. YLL rates decreased across the five leading Level 2 causes in all SDI quintiles. The leading causes of YLLs in 1990—neonatal disorders, lower respiratory infections, and diarrhoeal diseases—were ranked second, fourth, and fifth, in 2017. Meanwhile, estimated YLLs increased for ischaemic heart disease (ranked first in 2017) and stroke (ranked third), even though YLL rates decreased. Population growth contributed to increased total deaths across the 20 leading Level 2 causes of mortality between 2007 and 2017. Decreases in the cause-specific mortality rate reduced the effect of population growth for all but three causes: substance use disorders, neurological disorders, and skin and subcutaneous diseases. Interpretation Improvements in global health have been unevenly distributed among populations. Deaths due to injuries, substance use disorders, armed conflict and terrorism, neoplasms, and cardiovascular disease are expanding threats to global health. For causes of death such as lower respiratory and enteric infections, more rapid progress occurred for children than for the oldest adults, and there is continuing disparity in mortality rates by sex across age groups. Reductions in the death rate of some common diseases are themselves slowing or have ceased, primarily for NCDs, and the death rate for selected causes has increased in the past decade. Funding Bill & Melinda Gates Foundation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Present and future Köppen-Geiger climate classification maps at 1-km resolution

            We present new global maps of the Köppen-Geiger climate classification at an unprecedented 1-km resolution for the present-day (1980–2016) and for projected future conditions (2071–2100) under climate change. The present-day map is derived from an ensemble of four high-resolution, topographically-corrected climatic maps. The future map is derived from an ensemble of 32 climate model projections (scenario RCP8.5), by superimposing the projected climate change anomaly on the baseline high-resolution climatic maps. For both time periods we calculate confidence levels from the ensemble spread, providing valuable indications of the reliability of the classifications. The new maps exhibit a higher classification accuracy and substantially more detail than previous maps, particularly in regions with sharp spatial or elevation gradients. We anticipate the new maps will be useful for numerous applications, including species and vegetation distribution modeling. The new maps including the associated confidence maps are freely available via www.gloh2o.org/koppen.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

              Summary Background Lower respiratory infections are a leading cause of morbidity and mortality around the world. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2016, provides an up-to-date analysis of the burden of lower respiratory infections in 195 countries. This study assesses cases, deaths, and aetiologies spanning the past 26 years and shows how the burden of lower respiratory infection has changed in people of all ages. Methods We used three separate modelling strategies for lower respiratory infections in GBD 2016: a Bayesian hierarchical ensemble modelling platform (Cause of Death Ensemble model), which uses vital registration, verbal autopsy data, and surveillance system data to predict mortality due to lower respiratory infections; a compartmental meta-regression tool (DisMod-MR), which uses scientific literature, population representative surveys, and health-care data to predict incidence, prevalence, and mortality; and modelling of counterfactual estimates of the population attributable fraction of lower respiratory infection episodes due to Streptococcus pneumoniae, Haemophilus influenzae type b, influenza, and respiratory syncytial virus. We calculated each modelled estimate for each age, sex, year, and location. We modelled the exposure level in a population for a given risk factor using DisMod-MR and a spatio-temporal Gaussian process regression, and assessed the effectiveness of targeted interventions for each risk factor in children younger than 5 years. We also did a decomposition analysis of the change in LRI deaths from 2000–16 using the risk factors associated with LRI in GBD 2016. Findings In 2016, lower respiratory infections caused 652 572 deaths (95% uncertainty interval [UI] 586 475–720 612) in children younger than 5 years (under-5s), 1 080 958 deaths (943 749–1 170 638) in adults older than 70 years, and 2 377 697 deaths (2 145 584–2 512 809) in people of all ages, worldwide. Streptococcus pneumoniae was the leading cause of lower respiratory infection morbidity and mortality globally, contributing to more deaths than all other aetiologies combined in 2016 (1 189 937 deaths, 95% UI 690 445–1 770 660). Childhood wasting remains the leading risk factor for lower respiratory infection mortality among children younger than 5 years, responsible for 61·4% of lower respiratory infection deaths in 2016 (95% UI 45·7–69·6). Interventions to improve wasting, household air pollution, ambient particulate matter pollution, and expanded antibiotic use could avert one under-5 death due to lower respiratory infection for every 4000 children treated in the countries with the highest lower respiratory infection burden. Interpretation Our findings show substantial progress in the reduction of lower respiratory infection burden, but this progress has not been equal across locations, has been driven by decreases in several primary risk factors, and might require more effort among elderly adults. By highlighting regions and populations with the highest burden, and the risk factors that could have the greatest effect, funders, policy makers, and programme implementers can more effectively reduce lower respiratory infections among the world's most susceptible populations. Funding Bill & Melinda Gates Foundation.
                Bookmark

                Author and article information

                Contributors
                l.staadegaard@nivel.nl
                Journal
                Influenza Other Respir Viruses
                Influenza Other Respir Viruses
                10.1111/(ISSN)1750-2659
                IRV
                Influenza and Other Respiratory Viruses
                John Wiley and Sons Inc. (Hoboken )
                1750-2640
                1750-2659
                13 July 2021
                November 2021
                : 15
                : 6 ( doiID: 10.1111/irv.v15.6 )
                : 732-741
                Affiliations
                [ 1 ] Nivel (Netherlands Institute for Health Services Research) Utrecht The Netherlands
                [ 2 ] Royal Centre for Disease Control Ministry of Health Thimphu Bhutan
                [ 3 ] Department of Immunization and Communicable Diseases Ministry of Health Brasilia Brazil
                [ 4 ] Subdepartamento Enfermedades Virales Instituto de Salud Pública de Chile Santiago Chile
                [ 5 ] Sección Virus Respiratorios, Subdepartamento Enfermedades Virales Instituto de Salud Publica de Chile Santiago Chile
                [ 6 ] Department of Infectious Diseases Epidemiology National Institute of Public Health Prague Czech Republic
                [ 7 ] Department of Epidemiology and Biostatistics, Third Faculty of Medicine Charles University Prague Czech Republic
                [ 8 ] National Reference Laboratory for Influenza and Other Respiratory Viruses National Institute of Public Health Prague Czech Republic
                [ 9 ] Universidad Agraria del Ecuador Guayaquil Ecuador
                [ 10 ] Instituto Nacional de Investigación en Salud Pública (INSPI) Centro de Referencia Nacional de Influenza y otros Virus Respiratorios Guayaquil Ecuador
                [ 11 ] National Institute for Public Health and the Environment Bilthoven The Netherlands
                [ 12 ] Institute of Environmental Science and Research Limited (ESR) National Centre for Biosecurity and Infectious Disease (NCBID) Upper Hutt New Zealand
                [ 13 ] Instituto Nacional de Saúde Doutor Ricardo Jorge Lisbon Portugal
                [ 14 ] Ministry of Health Singapore
                [ 15 ] Saw Swee Hock School of Public Health Singapore
                [ 16 ] National Centre for Infectious Diseases Singapore
                [ 17 ] Centre for Respiratory Disease and Meningitis National Institute for Communicable Diseases Johannesburg South Africa
                [ 18 ] School of Public Health University of Witwatersrand Johannesburg South Africa
                [ 19 ] National Centre of Epidemiology, CIBER Epidemiología y Salud Pública (CIBERESP) Institute of Health Carlos III (ISCIII) Madrid Spain
                [ 20 ] Sanofi Pasteur Lyon France
                Author notes
                [*] [* ] Correspondence

                Lisa Staadegaard, Nivel (Netherlands Institute for Health Services Research), Otterstraat 118, 3513CR Utrecht, The Netherlands.

                Email: l.staadegaard@ 123456nivel.nl

                Author information
                https://orcid.org/0000-0002-6985-3541
                https://orcid.org/0000-0002-2262-1102
                https://orcid.org/0000-0002-0804-2729
                https://orcid.org/0000-0003-0376-2302
                https://orcid.org/0000-0002-1704-2245
                https://orcid.org/0000-0002-1503-2481
                Article
                IRV12885
                10.1111/irv.12885
                8542954
                34255934
                543067eb-b73c-490f-a8ad-3055e3109318
                © 2021 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 01 June 2021
                : 14 June 2021
                Page count
                Figures: 6, Tables: 0, Pages: 10, Words: 5989
                Funding
                Funded by: Sanofi/AstraZeneca , doi 10.13039/100004325;
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                November 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.8 mode:remove_FC converted:25.10.2021

                Infectious disease & Microbiology
                epidemiology,respiratory syncytial virus,seasonality,surveillance

                Comments

                Comment on this article